checkAd

     460  0 Kommentare Aquestive Therapeutics to Participate in Three Investor Conferences in September

    WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in three upcoming investor conferences in September as follows:

    • H.C. Wainwright 23rd Annual Global Investment Conference: on demand corporate presentation available from September 13 - 15
    • Lake Street Virtual Best Ideas Growth (BIG5) Conference: available for investor meetings on Tuesday, September 14
    • 2021 Cantor Virtual Global Healthcare Conference: virtual corporate presentation on Thursday, September 30 at 8:00 a.m. ET

    A webcast of each presentation will be available on the “Events and Presentation” page of the Investors section of the Company’s website. A replay of each webcast will be available for 90 days following the events. For more information, please visit investors.aquestive.com.

    About Aquestive Therapeutics

    Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan (clobazam) oral film, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm, and has proven capabilities for drug development and commercialization.

    Lesen Sie auch

    Forward-Looking Statement
    Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement of Libervant and other product candidates through the regulatory and development pipeline and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approvals of our product candidates; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; sale of and demand for our products; our liquidity and availability of capital resources; customer demand for our products and services; customers’ ability to pay for goods and services; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Aquestive Therapeutics to Participate in Three Investor Conferences in September WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic …